Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)

被引:69
作者
Fischer, Dagmar-Christiane [1 ]
Jacoby, Ulrike [1 ]
Pape, Lars [2 ]
Ward, Christopher J. [3 ]
Kuwertz-Broeking, Eberhard [4 ]
Renken, Catharina [1 ]
Nizze, Horst [5 ]
Querfeld, Uwe [6 ]
Rudolph, Birgit [7 ]
Mueller-Wiefel, Dirk E. [8 ]
Bergmann, Carsten [9 ]
Haffner, Dieter [1 ]
机构
[1] Univ Rostock, Dept Pediat, D-2500 Rostock 1, Germany
[2] Hannover Med Sch, Dept Pediat, Hannover, Germany
[3] Mayo Clin, Dept Hypertens & Nephrol, Rochester, MN USA
[4] Univ Munster, Dept Pediat, Berlin, Germany
[5] Univ Rostock, Dept Pathol, Berlin, Germany
[6] Charite Campus Virchow Clin, Dept Pediat, Berlin, Germany
[7] Charite Campus Virchow Clin, Dept Pathol, Berlin, Germany
[8] Univ Hamburg, Dept Pediat, Hamburg, Germany
[9] Aachen Univ Hosp, Rhein Westfal TH Aachen, Dept Human Genet, Aachen, Germany
关键词
AKT-signalling; autosomal recessive polycystic kidney disease; fibrocystin; polyduction; immunohistochemistry; mTOR-pathway; PROTEIN-KINASE-B; MTOR PATHWAY; MAMMALIAN TARGET; DOMINANT; PKHD1; INHIBITION; GENE; FIBROCYSTIN; MECHANISMS; GROWTH;
D O I
10.1093/ndt/gfn744
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. Autosomal recessive polycystic kidney disease (ARPKD) [MIM 263200] belongs to a group of congenital hepatorenal fibrocystic syndromes and is caused by mutations in the PKHD1 gene encoding the multidomain protein fibrocystin/polyductin (FPC). The serine-threonine kinase mammalian target of rapamycin (mTOR) is one of the most important gate-keepers integrating numerous signals related to cell proliferation and growth. Whereas the direct activation of mTOR has been shown recently in autosomal-dominant PKD, no data are available on the role of mTOR signalling in proliferation and progression of ARPKD. Methods. Formalin-fixed and paraffin-embedded kidney specimens obtained during nephrectomy from children with ARPKD (n = 12) were used for immunohistochemical investigation of FPC expression (monoclonal antibody (mAb) 18, mAb 5a), proliferative activity (Ki-67) and activation of the mTOR pathway. Kidney specimens from children (n = 4) who died from causes not associated with kidney disease served as controls. For the detection of AKT, mTOR and S6K antibodies specifically recognizing the activated (phosphorylated) isoforms of these proteins were used. In all patients mutation analysis of the PKHD1 gene was performed. Results. In 10 out of 12 patients, we could confirm the diagnosis by the identification of PKHD1 mutations. The tubular cyst epithelium of all kidney specimens stained strongly positive with the FPC-specific monoclonal antibody (mAb) 18 but only very faint signals were obtained with mAb 5a. In contrast, healthy kidneys showed rather weak signals with both FPC-specific mAbs, indicating dysregulated expression of FPC in our patients. Phosphorylated AKT as well as activated mTOR and its down-stream effector S6K were strongly expressed in cystic epithelia of all kidney specimens but not in control tissues. No association between the activation of this pathway and the proliferative activity (Ki-67 expression) was observed. Conclusions. Our results point to a central role of AKT/mTOR signalling in ARPKD and justify further investigations to evaluate the therapeutic potential of mTOR inhibitors in ARPKD patients.
引用
收藏
页码:1819 / 1827
页数:9
相关论文
共 61 条
[1]   When translation meets transformation: the mTOR story [J].
Averous, J. ;
Proud, C. G. .
ONCOGENE, 2006, 25 (48) :6423-6435
[2]   Renal cystic disease: New insights for the clinician [J].
Avner, Ellis D. ;
Sweeney, William E., Jr. .
PEDIATRIC CLINICS OF NORTH AMERICA, 2006, 53 (05) :889-+
[3]   Multi-exon deletions of the PKHD1 gene cause autosomal recessive polycystic kidney disease (ARPKD) -: art. no. e63 [J].
Bergmann, C ;
Küpper, F ;
Schmitt, CP ;
Vester, U ;
Neuhaus, TJ ;
Senderek, J ;
Zerres, K .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (10) :e63
[4]   Algorithm for efficient PKHD1 mutation screening in autosomal recessive polycystic kidney disease (ARPKD) [J].
Bergmann, C ;
Küpper, F ;
Domia, C ;
Schneider, F ;
Senderek, J ;
Zerres, K .
HUMAN MUTATION, 2005, 25 (03) :225-231
[5]   PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD) [J].
Bergmann, C ;
Senderek, J ;
Küpper, F ;
Schneider, F ;
Dornia, C ;
Windelen, E ;
Eggermann, T ;
Rudnik-Schöneborn, S ;
Kirfel, J ;
Furu, L ;
Onuchic, LE ;
Rossetti, S ;
Harris, PC ;
Somlo, S ;
Guay-Woodford, L ;
Germino, GG ;
Moser, M ;
Büttner, R ;
Zerres, K .
HUMAN MUTATION, 2004, 23 (05) :453-463
[6]   Spectrum of mutations in the gene for autosomal recessive polycystic kidney disease (ARPKD/PKHD1) [J].
Bergmann, C ;
Senderek, J ;
Sedlacek, B ;
Pegiazoglou, I ;
Puglia, P ;
Eggermann, T ;
Rudnik-Schöneborn, S ;
Furu, L ;
Onuchic, LF ;
De Baca, M ;
Germino, GG ;
Guay-Woodford, L ;
Somlo, S ;
Moser, M ;
Büttner, R ;
Zerres, K .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (01) :76-89
[7]  
BERGMANN C, 2008, COMPREHENSIVE PEDIAT, P155
[8]   Functional analysis of PKHD1 splicing in autosomal recessive polycystic kidney disease [J].
Bergmann, Carsten ;
Frank, Valeska ;
Kuepper, Fabian ;
Schmidt, Christa ;
Senderek, Jan ;
Zerres, Klaus .
JOURNAL OF HUMAN GENETICS, 2006, 51 (09) :788-793
[9]   Diagnosis, pathogenesis, and treatment prospects in cystic kidney disease [J].
Bergmann, Carsten ;
Frank, Valeska ;
Kuepper, Fabian ;
Kamitz, Dirk ;
Hanten, Jens ;
Berges, Peter ;
Mager, Silke ;
Moser, Markus ;
Kirfel, Jutta ;
Buettner, Reinhard ;
Senderek, Jan ;
Zerres, Klaus .
MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (03) :163-174
[10]   PROTEIN-KINASE-B (C-AKT) IN PHOSPHATIDYLINOSITOL-3-OH INASE SIGNAL-TRANSDUCTION [J].
BURGERING, BMT ;
COFFER, PJ .
NATURE, 1995, 376 (6541) :599-602